

## **ASX Announcement**

### **AdAlta investor presentation and Q&A conference call**

**MELBOURNE Australia, 1 August 2018**, AdAlta Limited (ASX: 1AD), the biotechnology company advancing its lead i-body candidate towards clinical development, is pleased to provide an updated presentation for the investor conference call today.

During the call, CEO Sam Cobb will provide an update on the progress AdAlta's lead therapeutic program for the treatment of Idiopathic Pulmonary Fibrosis, AD-214; discuss the Company's recent Placement to institutional and sophisticated investors and will cover any questions in a Q+A session on the Share Purchase Plan Offer, which is currently open to shareholders.

#### **Call details**

**Date and time:**

Wednesday, 1 August at 11 am AEST.

**Dial in details:**

Participant toll: +61 2 8038 5221

Participant toll-free: 1800 123 296

**Conference ID:** 5687897

A copy of the presentation is attached with this cover note and will also be made available on the corporate website at [www.adalta.com.au](http://www.adalta.com.au).

The session will be recorded and a copy will be made available via the company's website.

-ENDS-

## **Notes to Editors**

### **About AdAlta**

AdAlta Limited is an Australian based drug development company headquartered in Melbourne. The Company is focused on using its proprietary technology platform to generate i-bodies, a new class of protein therapeutics, with applications as therapeutic drugs to treat disease.

I-bodies are a promising, novel class of drugs that offer a new and more effective approach to treating a wide range of human diseases. They are identified and developed using our proprietary technology platform.

We have pioneered a technology that mimics the shape and stability of a crucial antigen-binding domain, that was discovered initially in sharks and then developed as a human protein. The result is a range of unique compounds, now known as i-bodies, for use in treating serious diseases.

AdAlta is developing its lead i-body candidate, AD-214, for the treatment of idiopathic pulmonary fibrosis (IPF) and other human fibrotic diseases, for which current therapies are sub-optimal and there is a high-unmet medical need.

The Company also plans to continue further drug discovery and development directed towards other drug targets and diseases with its i-body technology platform.

Further information can be found at: [www.adalta.com.au](http://www.adalta.com.au).

#### **For more information, please contact:**

##### **AdAlta Limited**

Sam Cobb, CEO

Tel: +61 (0)3 9479 5159

E: [s.cobb@adalta.com.au](mailto:s.cobb@adalta.com.au)



**AdAlta**  
next generation protein therapeutics

# AdAlta SPP Presentation

August 2018

**Sam Cobb, CEO and Managing Director**

**AdAlta Limited (ASX:1AD)**

[s.cobb@adalta.com.au](mailto:s.cobb@adalta.com.au)



# Disclaimer


Investment in AdAlta is subject to investment risk, including possible loss of income and capital invested. AdAlta does not guarantee any particular rate of return or performance, nor do they guarantee the repayment of capital.

This presentation is not an offer or invitation for subscription or purchase of or a recommendation of securities. It does not take into account the investment objectives, financial situation and particular needs of the investor. Before making any investment in AdAlta, the investor or prospective investor should consider whether such an investment is appropriate to their particular investment needs, objectives and financial circumstances and consult an investment advisor if necessary.

This presentation may contain forward-looking statements regarding the potential of the Company's projects and interests and the development and therapeutic potential of the company's research and development. Any statement describing a goal, expectation, intention or belief of the company is a forward-looking statement and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of discovering, developing and commercialising drugs that are safe and effective for use as human therapeutics and the financing of such activities. There is no guarantee that the Company's research and development projects and interests (where applicable) will receive regulatory approvals or prove to be commercially successful in the future. Actual results of further research could differ from those projected or detailed in this presentation. As a result, you are cautioned not to rely on forward-looking statements. Consideration should be given to these and other risks concerning research and development programs referred to in this presentation.

# AdAlta (1AD) investment summary

- ▶ A drug discovery and development company using its powerful technology platform to generate a promising new class of protein therapeutics, known as i-bodies, for treating a wide range of human diseases.
- ▶ **Investment highlights**
  - ▶ Finalised Placement of \$4.25m July 2018; launched SPP offer on same terms for existing shareholders
  - ▶ Initial focus on treating fibrosis – high unmet medical need
  - ▶ Advanced lead fibrosis drug candidate AD-214 with significant pre-clinical validation
  - ▶ Orphan drug designation USA FDA
  - ▶ Early commercialisation potential
  - ▶ Developing i-body pipeline to further expand opportunities for partnering of novel i-body platform
  - ▶ Experienced team with strong track record of drug development and ability to deliver



**AD-214**

# Placement and SPP July 2018



- ▶ Successfully closed \$4.25m via Placement with institutional and high net worth in July 2018
- ▶ Placement of 14,166,667 fully paid ordinary shares at a price of \$0.30 per share
  - **14.3% discount** to last traded price \$0.35
  - **16.7% discount** to 15-day VWAP of \$0.36
- ▶ Directors intend to take up a total of 522,450 shares, the issue of which will be subject to shareholder approval at the Annual General Meeting
- ▶ Share Purchase Plan launched to offer existing shareholders opportunity to take up shares on same terms
- ▶ Funds will be used for manufacturing of AD-214 and pre-clinical toxicology studies as well as i-body pipeline development and Corporate costs

# Financial position

Key financial details	
ASX code	1AD
Share price (31st July 2018)	AU\$0.30
Market capitalisation	AU\$34.65m
Shares on issue*	115,490,062
Escrowed shares (August 2018)	24,047,138
Options on issue	3,734,471
Current cash (30 <sup>th</sup> June 2018)	AU\$2.3m
Trading range (last 12 months)	AU\$0.20 to \$0.40
Average daily volume	41,951

Major shareholders	%
Yuuwa Capital LP	46.81
Platinum Asset Management	9.81
Citycastle Pty Ltd	4.60
National Nominees Limited	3.90
Meurs Holdings Pty Ltd	2.89
Other shareholders	29.36
<b>Total</b>	<b>100%</b>

## Share performance (last 12 months)



\*Excludes SPP shares and Director shares from Placement

# Extensive support from institutional investors and HNWs

- ▶ Top 20 shareholders 80%
- ▶ 61% institutional shareholders
- ▶ 11% HNWs with >500K shares each
- ▶ 4% founding academic institutions
- ▶ 2.6% Board, SAB and Management and 3,734,471 Options issued from 17 cents-\$1 under Employee Share Option Plan



Australian based venture capital \$40m fund



\$27b under management, global equities investor



Australian and international equities investor

# Significant achievements 2017/18

- ✓ Orphan Drug Designation (US FDA) of AdAlta i-body for treatment of IPF
- ✓ Completion of additional pre-clinical animal models in diseases of the lung, kidney, skin; strengthening broad anti-fibrotic data package of anti-CXCR4 i-body
- ✓ Publication of key data in *Scientific Reports* (a *Nature* publication)
- ✓ Presentation of AD-114 data at multiple fibrosis conferences including the IPF Summit
- ✓ Completion of several non human primate studies demonstrating safety of AD-114 but also safety of i-body platform
- ✓ Key AU patent granted covering AD-214




## SCIENTIFIC REPORTS

**OPEN** Anti-fibrotic Effects of CXCR4-Targeting i-body AD-114 in Preclinical Models of Pulmonary Fibrosis

Received: 8 November 2017  
Accepted: 24 January 2018  
Published online: 16 February 2018

K. Griffiths<sup>1,2</sup>, D. M. Habel<sup>1</sup>, J. Jaffar<sup>4</sup>, U. Binder<sup>5</sup>, W. G. Darby<sup>1,2</sup>, C. G. Hosking<sup>1,2</sup>, A. Skerra<sup>3</sup>, G. P. Westall<sup>4</sup>, C. M. Hogaboam<sup>1</sup> & M. Foley<sup>1,2</sup>

# AD-214 development: key milestones



# Expected news flow

- H1 2018**
  - ✓ Publication of AD-114 data in *Scientific Reports* demonstrating i-body application of pulmonary fibrosis with human tissue and animal model data
  - ✓ Investor and analyst briefing detailing application of the i-body for the undruggable targets such as GPCRs and ion channels
  - ✓ Commence manufacturing of AD-214 with Selexis and KBI
- H2 2018**
  - ▶ Expected R&D tax return of ~\$2m
  - ▶ Manufacturing update including cell line development
  - ▶ Publish i-body  $\frac{1}{2}$  life and eye fibrosis data
  - ▶ Preliminary non-human primate data with AD-214
- H1 2019**
  - ▶ Complete manufacturing including materials for tox program
  - ▶ Update on i-body pipeline development
- H2 2019**
  - ▶ 4 week NHP toxicology study
  - ▶ Regulatory discussions with US FDA
- H1 2020**
  - ▶ Phase I SAD/MAD study with AD-214

# Share Purchase Plan

- ▶ Eligible Shareholders have the opportunity to participate in the Share Purchase Plan to subscribe for up to \$15,000 (50,000) of new AdAlta shares
- ▶ The offer price per share under the SPP Offer will be 30 cents per share, being the same issue price as the Placement to institutional and sophisticated investors
- ▶ **Key Dates:**
  - Currently open
  - **SPP Offer closes 10 August 2018**
  - Completion announcement date (and notice of scale backs, if any) 15 August 2018
  - Allotment Date 15 August 2018
  - Dispatch Holding Statements 16 August 2018

# AdAlta Limited (ASX: 1AD) summary

- ▶ Successfully raised \$4.25m in Placement with institutional and high net worth investors, completed post quarter's end, securing funding for AD-214 to end of manufacturing
- ▶ SPP open now at same terms as Placement – closes on 10 August
- ▶ June cash position of \$2.3m, with ~\$2m R&D tax incentive expected in Q1 FY 19
- ▶ Initial focus on treating Idiopathic Pulmonary Fibrosis (IPF) and other fibrotic diseases - high unmet clinical need
- ▶ AD-214 has significant pre-clinical validation demonstrating broad anti-fibrotic and anti-inflammatory effects as well as safety

**Early commercialisation opportunity, with experienced management and Board to drive AD-214 development and secure technology platform partnerships / product licensing deals**



**Contact us:**

**Sam Cobb, CEO**

[s.cobb@adalta.com.au](mailto:s.cobb@adalta.com.au)

[www.adalta.com.au](http://www.adalta.com.au)

